RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 18
SP 22
OP 23
DO 10.1177/155989771218013
UL http://mdc.sagepub.com/content/12/18/22.abstract
AB Relaxin, a naturally occurring peptide, is associated with hemodynamic changes as well anti-ischemic, anti-inflammatory, and antifibrotic effects that may offer benefit to patients with acute heart failure (AHF). This article reports the results of the Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [RELAX-AHF; NCT00520806] trial designed to test the efficacy and safety of serelaxin, a recombinant version of human relaxin-2, in patients with AHF.